CA2992925A1 - Identification de peptides immunogenes de classe ii du complexe majeur d'histocompatibilite pour une immunotherapie - Google Patents

Identification de peptides immunogenes de classe ii du complexe majeur d'histocompatibilite pour une immunotherapie Download PDF

Info

Publication number
CA2992925A1
CA2992925A1 CA2992925A CA2992925A CA2992925A1 CA 2992925 A1 CA2992925 A1 CA 2992925A1 CA 2992925 A CA2992925 A CA 2992925A CA 2992925 A CA2992925 A CA 2992925A CA 2992925 A1 CA2992925 A1 CA 2992925A1
Authority
CA
Canada
Prior art keywords
cell
peptides
peptide
cancer
fold
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2992925A
Other languages
English (en)
Inventor
Brian J. Czerniecki
Gary K. Koski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Original Assignee
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2015/041034 external-priority patent/WO2016011432A2/fr
Application filed by University of Pennsylvania Penn filed Critical University of Pennsylvania Penn
Publication of CA2992925A1 publication Critical patent/CA2992925A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/812—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/828—Stomach
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70514—CD4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

L'invention concerne des compositions, des méthodes et des vaccins qui peuvent stimuler le système immunitaire et qui peuvent être utilisés pour le traitement de tumeurs malignes associées à une surexpression de la protéine HER-3. De telles compositions comprennent des épitopes de la protéine HER -3.
CA2992925A 2015-07-17 2016-03-04 Identification de peptides immunogenes de classe ii du complexe majeur d'histocompatibilite pour une immunotherapie Abandoned CA2992925A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
USPCT/US2015/041034 2015-07-17
PCT/US2015/041034 WO2016011432A2 (fr) 2014-07-17 2015-07-17 Identification de peptides immunogènes de classe ii du complexe majeur d'histocompatibilité pour une immunothérapie
PCT/US2016/021042 WO2017014810A1 (fr) 2015-07-17 2016-03-04 Identification de peptides immunogènes de classe ii du complexe majeur d'histocompatibilité pour une immunothérapie

Publications (1)

Publication Number Publication Date
CA2992925A1 true CA2992925A1 (fr) 2017-01-26

Family

ID=57835029

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2992925A Abandoned CA2992925A1 (fr) 2015-07-17 2016-03-04 Identification de peptides immunogenes de classe ii du complexe majeur d'histocompatibilite pour une immunotherapie
CA2992937A Abandoned CA2992937A1 (fr) 2015-07-17 2016-04-07 Identification de peptides immunogenes de classe ii du complexe majeur d'histocompatibilite pour une immunotherapie

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2992937A Abandoned CA2992937A1 (fr) 2015-07-17 2016-04-07 Identification de peptides immunogenes de classe ii du complexe majeur d'histocompatibilite pour une immunotherapie

Country Status (5)

Country Link
EP (2) EP3325005A4 (fr)
JP (3) JP2018527286A (fr)
CN (1) CN107206045A (fr)
CA (2) CA2992925A1 (fr)
WO (2) WO2017014810A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2992925A1 (fr) * 2015-07-17 2017-01-26 The Trustees Of The University Of Pennsylvania Identification de peptides immunogenes de classe ii du complexe majeur d'histocompatibilite pour une immunotherapie
US20220370496A1 (en) * 2019-09-13 2022-11-24 H. Lee Moffitt Cancer Center And Research Institute, Inc. Her3 pulsed dc1 therapy

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5183884A (en) * 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
IL145926A0 (en) * 2001-10-15 2002-07-25 Mor Research Applic Ltd Peptide epitopes of mimotopes useful in immunomodulation
EP2258712A3 (fr) * 2002-03-15 2011-05-04 Multicell Immunotherapeutics, Inc. Compositions et procédés permettant d'initier ou d'ameliorer les réponses des cellules T limitées par le complexe majeur d 'histocompatibilité de classe I ou II et un anticorps au moyen de motifs d'ARN non codants immunomodulateurs
AU2003218600C1 (en) * 2002-03-26 2009-12-17 Zensun (Shanghai) Science & Technology Co., Ltd. ERBB3 based methods and compositions for treating neoplasms
US7700299B2 (en) * 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
EP2049568A2 (fr) * 2006-04-07 2009-04-22 Københavns Universitet Fragments peptidiques dérivés du récepteur erbb
WO2007144772A2 (fr) * 2006-06-15 2007-12-21 Novartis Ag Régime de vaccination multidose à adjuvant limité contre la grippe
JP5384672B2 (ja) * 2009-02-24 2014-01-08 エフ．ホフマン−ラ ロシュ アーゲー 癌のマーカーとしてのｓ−ＥｒｂＢ−３の使用
JP2010200693A (ja) * 2009-03-04 2010-09-16 Chiyoda Kako Kensetsu Kk 樹状細胞ワクチン製造用培養装置並びに樹状細胞の製造方法
US8765383B2 (en) * 2009-04-07 2014-07-01 Genomic Health, Inc. Methods of predicting cancer risk using gene expression in premalignant tissue
AU2010278702C1 (en) * 2009-07-31 2016-07-14 Forsyth Dental Infirmary For Children Programming of cells for tolerogenic therapies
RU2575978C2 (ru) * 2010-03-15 2016-02-27 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Система и способ получения и хранения активированных зрелых дендритных клеток
JP2014516960A (ja) * 2011-05-19 2014-07-17 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） 抗ヒトｈｅｒ３抗体及びその使用
EP3590538A1 (fr) * 2011-12-05 2020-01-08 Novartis AG Anticorps dirigés contre le récepteur 3 du facteur de croissance épidermique (her3)
SG11201602291TA (en) * 2013-09-30 2016-04-28 Daiichi Sankyo Co Ltd Nucleic acid biomarker and use thereof
WO2016011343A1 (fr) * 2014-07-17 2016-01-21 The Trustees Of The University Of Pennsylvania Vaccins à base de peptides de protéine her3 et de cellules dendritiques
CA2992925A1 (fr) * 2015-07-17 2017-01-26 The Trustees Of The University Of Pennsylvania Identification de peptides immunogenes de classe ii du complexe majeur d'histocompatibilite pour une immunotherapie

Also Published As

Publication number Publication date
WO2017014816A1 (fr) 2017-01-26
WO2017014810A1 (fr) 2017-01-26
JP2018527286A (ja) 2018-09-20
JP2021043204A (ja) 2021-03-18
JP2018521953A (ja) 2018-08-09
EP3325005A1 (fr) 2018-05-30
EP3324990A1 (fr) 2018-05-30
EP3324990A4 (fr) 2019-04-03
CA2992937A1 (fr) 2017-01-26
CN107206045A (zh) 2017-09-26
EP3325005A4 (fr) 2019-03-27

Similar Documents

Publication Publication Date Title
RU2464275C2 (ru) Пептидные вакцины для раков, экспрессирующих опухолеспецифические антигены
US20210163573A1 (en) Identification of immunogenic mhc class ii peptides for immune-based therapy
KR20180121530A (ko) 비소세포 폐암 및 기타 암에 대한 면역요법에서의 사용을 위한 펩티드 및 펩티드의 조합
PT2837383T (pt) Agente de indução de imunidade
KR20180038550A (ko) 다양한 암의 면역요법 치료에서의 사용을 위한 신규 펩티드, 펩티드의 조합 및 골격
CN107148469B (zh) 肿瘤抗原肽
EA037547B1 (ru) Способ активации хелперных т-клеток
CN109311955B (zh) 一种新的肿瘤特异性多肽及其应用
CN102481333A (zh) 免疫诱导剂
AU2015362469A1 (en) Tumor antigen peptide
CA2992925A1 (fr) Identification de peptides immunogenes de classe ii du complexe majeur d'histocompatibilite pour une immunotherapie
AU2019201194B2 (en) Identification of immunogenic MHC Class II peptides for immune-based therapy
MX2011006755A (es) Peptidos clorf59 y vacunas que los incluyen.
WO2023224096A1 (fr) Vaccin contre le cancer utilisant un cocktail d'antigènes courants du cancer, un agent thérapeutique des cellules tcr/car-t, procédé de diagnostic compagnon et procédé de diagnostic du risque d'apparition du cancer par détection de cellules cancéreuses circulant dans le sang
KR102267463B1 (ko) 암 항원 펩티드
JP5279063B2 (ja) Ｈｌａ−ａ２拘束性抗原ペプチドおよびその用途
CA2955456C (fr) Identification de peptides immunogenes de classe ii du complexe majeur d'histocompatibilite pour une immunotherapie
Seliger et al. Cytotoxic T Cell Epitopes and Tissue
HK40002813B (en) Novel tumor-specific polypeptide and application thereof

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20220525